Español

Enrollment in PREVENT will be closing on September 30, 2026!

Click here to learn more.

ALL ALS PREVENT STUDY

Transforming the Landscape of ALS Research

Join Our Study

Seeking First Degree Relatives of Patients with ALS or FTD Without Current Symptoms of ALS

Important Update:

The PREVENT ALL ALS study, which enrolls people at increased genetic risk of developing ALS, has exceeded their enrollment goals, due to the overwhelming support of the at risk community! As a result, enrollment in PREVENT will be closing on September 30, 2026. Note: Enrollment for the ASSESS ALL ALS study, which enrolls people living with ALS and people living without ALS (and not at genetic risk), will continue to enroll past Sept. 30, 2026.

Why is the PREVENT Study Necessary?

Research into the natural history of ALS, including its earliest manifestations in asymptomatic ALS gene carriers, is a top priority. These research efforts are expected to result in knowledge that can lead to more informative, targeted, and personalized drug development, taking the field one step closer toward the goal of halting, repairing, and/or preventing ALS.

Middle aged African American woman in peach colored shirt
Middle aged man with ALS in a blue shirt and a young female nurse

Who Can Participate in the PREVENT Study?

  • Age 18 years of age or older
  • Capable of providing informed consent
    Willing to follow study procedures
  • First-degree relative of a known carrier of any ALS causative gene (including either symptomatic ALS/Frontotemporal dementia (FTD) patients or asymptomatic ALS gene carriers)
  • First-degree relative of an individual with a compelling history of ALS and/or FTD causative gene with a compelling family history of genetic ALS involving at least 2 close relatives with ALS or FTD, at least one of whom had ALS.
  • Access to a smartphone or tablet, and internet (need not be in the home – access to a public library or other available computer with internet connection is sufficient)

Who CAN NOT Participate in the PREVENT Study?

  • Noncompliance with protocol requirements
  • Evidence of neurological signs or symptoms concerning for ALS of FTD, at the discretion of the site investigator
  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness.
  • Clinically significant, unstable medical conditions that may prevent 12 month follow-up
Middle aged couple sitting on a bench looking at a tablet

What Should I Expect When Participating In This Study?

  • Participants will be presented an “Informed Consent Form” outlining the details of the study and will be given the opportunity to ask all questions before agreeing to participate.
  • Participation is completely voluntary. While participants are encouraged to remain in the study for as long as possible, discontinuation of the study is acceptable at any time, for any reason.
  • Participants will complete study visits to gather clinical data based on designated cohort study schedule:
    • Cohort 1: In-person or remote study visits every 4 months for up to 2 years.
    • Cohort 2: In-person study visits once a year for up to 2 years.
  • Biofluid samples (blood and optional Cerebrospinal fluid (CSF)) will be collected at study in-person visits and blood samples will be collected via home visits for remote participants.
  • Participants will complete short self-report questionnaires and speech tasks via an online portal.

How Will My Data and/or Samples Be Used?

  • Biofluids will be stored in a central biorepository and shared with researchers upon request.
  • Clinical data will be stored in NeuroBank, the study electronic data capture system, and the AMP ALS portal, and will be shared with requesting researchers.

If you wish for a member of the study team to contact you about the ALL ALS Consortium, please click the button below:

English
Español
Participate Skip to content